Drug intelligence / Profile preview

BGP-31172

Development stage: Unknown
Lead developer: BridGene Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**BGP-31172** is a highly potent and selective covalent inhibitor targeting FGFR3, demonstrating promising antitumor activity in patients with FGFR3-altered metastatic urothelial carcinoma (mUC), including those previously treated with FGFR inhibitors. In early clinical data, it was well-tolerated at 200 mg BID, with low rates of common FGFRi-related treatment-emergent adverse events (TEAEs) such as palmar-plantar erythrodysesthesia (PPE, 7%), onycholysis (0%), and retinopathy (0%). Non-clinical toxicology studies in rats and dogs over 28 days supported its safety profile, positioning it as a potential next-generation therapy for FGFR-driven cancers.

Other names: Selective covalent FGFR3 inhibitorBridGene FGFR3 inhibitor

Targets

FGFR3 (Fibroblast growth factor receptor 3)

Beyond the preview

Go deeper on BGP-31172.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGP-31172.

Explore the full profile